Is AOD-9604 Legal in California?

What AOD-9604 Actually Is

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (hGH), corresponding to residues 176 to 191 of the hGH C-terminus. Metabolic Pharmaceuticals Ltd. Originally developed it as an anti-obesity drug candidate under the brand name Tyr-hGH Frag 176 to 191. The compound was designed to retain the lipolytic activity of native hGH without stimulating IGF-1 production or causing the glucose-intolerance side effects seen with full-length hGH administration. [1]

Mechanism of Action

AOD-9604 binds beta-3 adrenergic receptors in adipose tissue, stimulating fat breakdown (lipolysis) while simultaneously inhibiting new fat cell formation (lipogenesis). Unlike recombinant hGH, it does not appear to meaningfully raise serum IGF-1 at doses used in human trials. [2] This receptor selectivity is why researchers originally hoped it would be both effective and metabolically safe.

Clinical Trial History

Metabolic Pharmaceuticals ran the compound through several phase II trials in the early 2000s. The METAOD003 trial (N=300, 12 weeks) tested oral AOD-9604 at doses of 1 mg and 9 mg per day versus placebo in adults with a body mass index between 27 and 35 kg/m². The 1 mg arm produced a statistically significant reduction in body fat compared with placebo (P<0.05), but the effect size was modest at approximately 1.2 kg. [3] A subsequent phase IIb trial failed to replicate a clinically meaningful primary endpoint, and Metabolic Pharmaceuticals discontinued the obesity development program. The FDA never granted approval for AOD-9604 as a finished drug product for any indication.

Federal Legal Framework: Where AOD-9604 Stands with the FDA

AOD-9604 is not a scheduled controlled substance under the Controlled Substances Act. That distinction matters. It is not in Schedule III alongside anabolic steroids, and it is not in Schedule I. [4] However, the absence of scheduling does not mean the compound is freely available for human use.

The FDA Bulks List and 503A Compounding

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a licensed pharmacist may compound a drug product from bulk drug substances for an individual patient with a valid prescription, provided the substance appears on the FDA's 503A bulks list or meets specific criteria. [5] The FDA has been evaluating AOD-9604 under this framework. As of 2024, AOD-9604 remains in the "Category 2" evaluation status for 503A purposes, meaning the FDA has received insufficient clinical data to support its inclusion on the positive list. [6]

Category 2 does not constitute an outright prohibition, but it signals active regulatory scrutiny. Compounding pharmacies that dispense Category 2 substances operate with real enforcement risk. The FDA has issued multiple warning letters to compounding pharmacies dispensing unapproved peptide bulk substances, explicitly citing concerns about patient safety, lack of evidence, and failure to meet compounding standards. [7]

503B Outsourcing Facilities

Section 503B of the FD&C Act governs outsourcing facilities, larger-scale compounders that may produce drugs without patient-specific prescriptions for distribution to health-system practitioners. [8] AOD-9604 is not on the FDA's 503B bulks list. A 503B outsourcing facility legally cannot compound AOD-9604 for distribution in the United States. This distinction affects the supply chain: any California compounding pharmacy receiving AOD-9604 from a 503B outsourcing facility would be receiving a product that does not comply with federal compounding law.

Research and IND Pathways

A pharmaceutical company or academic institution may investigate AOD-9604 in humans under an Investigational New Drug (IND) application filed with the FDA. [9] ClinicalTrials.gov currently lists no actively recruiting U.S. Trials for AOD-9604 as of July 2024, though completed trial records from Metabolic Pharmaceuticals remain accessible. Outside of an IND, using AOD-9604 in human subjects outside the compounding framework constitutes use of an unapproved new drug under 21 U.S.C. § 321(p).

California State Legal Framework

California does not have a separate state law that either explicitly legalizes or explicitly bans AOD-9604. The compound's fate in California is therefore governed by the intersection of federal FDA rules, the California Business and Professions Code (BPC), and California State Board of Pharmacy regulations.

California Board of Pharmacy Rules

The California State Board of Pharmacy regulates compounding under BPC §§ 4126 to 4129.9. California-licensed pharmacies that compound drug products must comply with both state rules and federal law, including the FD&C Act's compounding provisions. [10] A California pharmacy that compounds AOD-9604 for a patient-specific prescription is operating under the 503A framework federally and under BPC § 4127 at the state level, which requires that compounded products not be commercially available and that there is a valid prescription.

Medical Practice Act Considerations

California's Medical Practice Act (BPC § 2050 et seq.) permits licensed physicians to prescribe drugs for off-label uses when there is a legitimate medical purpose and the physician exercises sound clinical judgment. [11] Off-label prescribing is not inherently unlawful in California. A physician who prescribes AOD-9604 through a compliant 503A pharmacy for a patient with a documented clinical indication is engaging in off-label prescribing of a compounded product. That practice is legal under California and federal law, provided the compound itself is sourced correctly and the compounding pharmacy meets applicable quality standards.

The Gray Zone: What "Compliant" Actually Requires

Given the FDA's Category 2 evaluation status for AOD-9604 under 503A, the gray zone is real. The FDA has not prohibited 503A compounders from using AOD-9604 outright, but it has signaled that evidence supporting its safety and efficacy is insufficient. [6] California physicians prescribing it and pharmacies compounding it are operating in an area where federal enforcement action is possible, even when all state procedural requirements are met.

The HealthRX clinical team uses the following four-factor compliance framework when evaluating whether a California AOD-9604 prescription is defensible:

1. Documented clinical indication. The prescribing physician has recorded a specific, individualized clinical rationale in the patient's chart (e.g., documented adipose tissue excess with a BMI of 27 to 40 kg/m² and failure of lifestyle interventions, or a body composition goal in the context of a supervised weight-management program).
2. 503A-compliant pharmacy. The dispensing pharmacy is a California-licensed 503A compounding pharmacy that sources AOD-9604 from an FDA-registered bulk drug substance supplier, conducts certificate-of-analysis (CoA) testing, and does not use a 503B outsourcing facility as its supplier for this compound.
3. Patient-specific prescription. The prescription names the individual patient, specifies the exact dosage form, strength, and quantity, and is issued only after a clinician-patient relationship has been established (including a medical history, physical, or telehealth evaluation meeting California's standard of care).
4. Informed consent documentation. The patient has received, read, and signed an informed consent document that discloses the investigational and unapproved nature of AOD-9604, the limits of available clinical evidence, and the known and theoretical risk profile.

How to Get AOD-9604 in California Legally

Getting AOD-9604 in California through a compliant pathway requires three discrete steps. None of them involve purchasing from research-chemical websites or overseas peptide suppliers, both of which carry meaningful legal exposure for individual buyers. [12]

Step 1: Establish Care with a Licensed California Physician

A telehealth evaluation with a California-licensed physician satisfies the patient-prescriber relationship requirement under California law, provided the encounter includes a review of medical history, relevant labs, and documentation of the clinical indication. [13] During that visit, the physician should assess BMI, body composition goals, relevant metabolic labs (fasting glucose, HbA1c, lipid panel, IGF-1), and any contraindications such as active malignancy, since hGH-fragment peptides carry a theoretical concern in patients with certain cancers, even though AOD-9604 does not meaningfully raise IGF-1.

Step 2: Receive a Patient-Specific Compounded Prescription

The physician transmits a patient-specific prescription to a California-licensed 503A compounding pharmacy. The prescription should specify AOD-9604 at the intended dose (commonly 300 mcg subcutaneously once daily in the trials, though clinical practice varies), the dosage form (typically a sterile injectable solution), the quantity (a 30-day supply), and any diluent specifications. The pharmacy's CoA for the bulk substance should confirm identity, purity of 98% or higher, and absence of endotoxins at levels meeting USP <85> standards for injectable preparations.

Step 3: Understand the Monitoring Requirements

No specific FDA-approved monitoring protocol exists for AOD-9604 because the drug never received approval. Physicians at HealthRX recommend a minimum of quarterly check-ins that include body composition assessment, fasting glucose, and IGF-1 to confirm the compound is not producing unexpected growth factor elevations. Any adverse event should be reported to the FDA's MedWatch program. [14]

What the Evidence Actually Says About Efficacy

The clinical evidence for AOD-9604 is limited. Summarizing it accurately matters for informed consent and for setting patient expectations.

Phase II Trial Results

The METAOD003 trial showed a modest but statistically significant reduction in body fat at the 1 mg oral dose over 12 weeks in a population with BMI between 27 and 35 kg/m². [3] A separate 24-week dose-ranging study showed no significant difference from placebo at doses above 1 mg, which was an unexpected finding that partly explains why the development program was discontinued. An animal study published in the journal Obesity Research found that AOD-9604 reduced fat mass in obese Zucker rats by approximately 50% over 8 weeks of subcutaneous administration, but rodent pharmacokinetics do not translate reliably to humans. [2]

Absence of Long-Term Human Safety Data

No published randomized controlled trial has evaluated AOD-9604 for longer than 24 weeks in humans. The longest-duration safety data available come from Metabolic Pharmaceuticals' clinical program, which did not detect significant adverse effects on glucose metabolism, IGF-1, or cardiovascular parameters in trials lasting up to 12 weeks. [3] The absence of published long-term data means that clinicians prescribing AOD-9604 are working without the safety evidence base that accompanies FDA-approved anti-obesity medications such as semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound). The STEP-1 trial (N=1,961), for instance, provided 68 weeks of safety and efficacy data for semaglutide 2.4 mg, showing 14.9% mean body weight reduction versus 2.4% with placebo. [15] AOD-9604 has no comparable evidence base.

Guideline Position

Neither the Endocrine Society nor the American Association of Clinical Endocrinologists (AACE) currently lists AOD-9604 in their obesity pharmacotherapy guidelines. The 2023 AACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity do not mention AOD-9604 among recommended or investigational agents. [16] The American Society of Bariatric Physicians has similarly not endorsed it.

Enforcement Risk and Buyer Warnings

The FDA's enforcement record on unapproved peptides is not theoretical. In 2020 and again in 2022, the FDA sent warning letters to specific compounding pharmacies for distributing peptide products including BPC-157, TB-500, and other bulk substances that the agency deemed neither safe nor suitable for compounding. [7] AOD-9604 has not been the direct subject of a public FDA warning letter as of July 2024, but the regulatory logic that underlies those letters applies to any Category 2 bulk substance.

Buyers who purchase AOD-9604 from online research-chemical suppliers, overseas peptide vendors, or any source that does not require a prescription are purchasing a product with no verifiable quality control, no confirmed identity or purity, and no legal standing as a pharmaceutical product for human use. The FDA has authority to seize such products under 21 U.S.C. § 334. [12] California's own Business and Professions Code § 4169 prohibits the purchase or receipt of prescription drugs from sources other than authorized distributors, which provides an additional state-level basis for enforcement.

As the FDA's guidance on compounding from bulk drug substances states: "FDA has significant concerns about the safety of patients who receive compounded drugs. FDA has found serious adverse events, including deaths, associated with compounded drugs." [5]

California Telehealth Access: Practical Considerations

California's telehealth laws, updated under the California Telehealth Advancement Act (BPC § 2290.5), permit prescribing via synchronous video or audio-only encounters without an in-person requirement for most medications, provided the standard of care is met. [13] This means a California patient can, in principle, consult a physician via a telehealth platform, receive an AOD-9604 prescription, and have it dispensed by a California-licensed compounding pharmacy, all without leaving home. The compounding pharmacy ships directly to the patient's California address.

Telehealth prescribing of compounded peptides is an area the California Medical Board monitors. Physicians who prescribe AOD-9604 should maintain documentation sufficient to demonstrate that the prescribing met the standard of care. The Medical Board's 2023 enforcement guidelines on telehealth specifically note that prescribing without an adequate medical history, physical examination findings, or diagnostic data may constitute unprofessional conduct. [11]

Comparing AOD-9604 to FDA-Approved Alternatives

Patients considering AOD-9604 for fat loss should understand where it sits relative to approved options. Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management and produced 14.9% mean weight loss at 68 weeks in STEP-1. [15] Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539). [17] Both carry strong safety data from trials lasting more than a year.

AOD-9604's best documented effect in humans is approximately 1.2 kg of fat loss at 12 weeks in a specific oral dose range. The clinical use case for AOD-9604 in California is therefore narrow: patients who have contraindications to GLP-1 receptor agonists, who have already achieved significant weight loss through other means and are targeting residual adipose tissue, or who are seeking a compounded peptide adjunct under close physician supervision.